TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01642212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Budesonide Suspension (MB-9)
Description: OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01137214

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilator
Description: All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive positive pressure ventilator
Description: All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
Study: NCT01106001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
Study: NCT01708824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary
Description: Dietary intervention to meet the target of~1. \<5 servings of red/processed meat weekly; \<2 servings would be processed meat~2. 2 servings of refined grains daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity intervention with the following targets:~1. General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~2. Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)
Study: NCT00816569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthokeratology contact lenses
Description: Wearing Orthokeratology lens in one eye of a keratoconus patient
Study: NCT02331394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese herbs formula: Shu Yu Wan
Description: The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
Study: NCT04395417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Patients were infiltrated with injection single dose 30 mg/2 ml 1500 kilodalton high molecular weight hyaluronic acid at the lateral epicondyle according to the standard technique.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolotherapy
Description: Patients were infiltrated with 5cc of dextrose 15% at the lateral epicondyle according to the standard technique. For solution, 1 cc 2% lidocaine, 5 cc 30% hypertonic dextrose and 4 cc 0.9 % isotonic were used.
Study: NCT00771485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FM-602
Description: Study of Efficacy of Bowel Preparation Before Colonoscopy

Intervention type: DRUG
Group type: OTHER
Intervention: Marketed Bowel Cleanser
Description: Marketed bowel cleanser
Study: NCT03080597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrEP Smart app
Description: English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart.
Study: NCT02770820

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04104165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter used for treatment of urinary retention
Study: NCT01106001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
Study: NCT03505398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated visual field
Description: recording visual attention based on central or peripheral visual information

Intervention type: PROCEDURE
Group type: OTHER
Intervention: automated visual field
Description: recording visual attention based on central or peripheral visual information
Study: NCT00679640

Intervention type: DRUG
Intervention: Candesartan
Description: Oral tablets
Study: NCT01402219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol injection 76%
Description: Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iodixanol
Description: Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
Study: NCT02031094

Intervention type: OTHER
Intervention: Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure
Description: Observational methods of measuring resting energy expenditure
Study: NCT02409472

Intervention type: OTHER
Group type: OTHER
Intervention: surveillance program after completion of primary treatment
Description: These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.

Intervention type: OTHER
Group type: OTHER
Intervention: surveillance program after completion of primary treatment
Description: These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
Study: NCT02077465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: 400 mg andecaliximab administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match Andecaliximab
Description: Placebo to match andecaliximab administered intravenously
Study: NCT03505398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated visual field
Description: recording visual attention based on central or peripheral visual information

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eye movements recording
Description: recording of explicit visual attention based on central or peripheral visual information

Intervention type: PROCEDURE
Group type: OTHER
Intervention: eye movements recording
Description: recording of explicit visual attention based on central or peripheral visual information
Study: NCT03337386

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: inferior vena cava collapsibility
Description: inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: subclavian vein collapsibility
Description: Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: central venous pressure
Description: ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
Study: NCT04758130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zamplo Digital Health Platform
Description: This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zamplo Digital Health Platform
Description: This application will be provided to patients and provide them with a method to track various data related to their metabolic disease.
Study: NCT00878878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison.
Study: NCT03966365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-122
Description: * PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* Route of administration: topical ophthalmic.
Study: NCT02539706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium 0,6mg/kg
Description: patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0,6mg/kg
Description: patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
Study: NCT01243268

Intervention type: DRUG
Intervention: Twynsta tablet
Description: Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
Study: NCT00716716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: As specified in the treatment arm
Study: NCT01624142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
Study: NCT03966365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Krytantek Ofteno®
Description: * - 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~* - Route of administration: topical ophthalmic.
Study: NCT01947218

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bronchial biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial biopsies

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of CO in exhaled air
Study: NCT00831376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levosalbutamol
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study: NCT01947218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of CO in exhaled air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of CO in exhaled air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of CO in exhaled air
Study: NCT00831376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic salbutamol
Description: Patients will be asked to take two puffs four times a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will be asked to take two puffs four times a day for 2 weeks
Study: NCT02193789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: deployment of through the scope covered metallic stent at the stricture site
Description: Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covered Self-expandable Metallic Stents
Study: NCT03505398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eye movements recording
Description: recording of explicit visual attention based on central or peripheral visual information
Study: NCT06057311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hippotherapy
Description: The participants in HT Group; received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study: NCT01591447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solithromycin
Description: A single oral dose of 1200 mg solithromycin (CEM-101)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin (CEM-101)
Description: A single oral dose of 1000 mg solithromycin
Study: NCT00481338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-rays
Description: X-rays (hip and knee) every 2 years

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological samples
Description: biological sample (blood and urine) every 2 years

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical information about osteoarthritis
Description: several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
Study: NCT04383366

Intervention type: DEVICE
Intervention: Pentacam® (Oculus, Inc., Wetzlar, Germany)
Description: Scheimpflug imaging

Intervention type: DEVICE
Intervention: Casia II (Tomey Germany, Nürnberg)
Description: Anterior segment optical coherence tomography

Intervention type: DEVICE
Intervention: Spectralis Anterion (Heidelberg Engineering, Heidelberg, Germany)
Description: Anterior segment optical coherence tomography
Study: NCT01012635

Intervention type: OTHER
Intervention: Hypnosis
Description: Hypnosis Training: Verbal suggestions from an audio recording (via headphones).

Intervention type: OTHER
Intervention: Meditation
Description: Meditation: focus on a single word (one) for the entire session.

Intervention type: OTHER
Intervention: Neurofeedback training
Description: Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.

Intervention type: OTHER
Intervention: Two different levels of tDCS
Description: Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
Study: NCT02583763

Intervention type: OTHER
Intervention: Echocardiography
Description: During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.

Intervention type: OTHER
Intervention: Echocardiography
Description: During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.

Intervention type: PROCEDURE
Intervention: Blood sample
Description: The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
Study: NCT06057311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine-Assisted Activities Therapy
Description: The participants in the EAAT Group received 12 sessions as 2 sessions a week for 6 weeks. Each therapy session lasted for an average of 20 min. The assessments were applied twice to all participants before and after the training. The treatments and assessments were performed by the same physiotherapist in the same environment.
Study: NCT02583763

Intervention type: PROCEDURE
Intervention: Blood sample
Description: The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
Study: NCT01654458

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GyneGals Support Group
Description: 12-week online (i.e. Internet-based), professionally-facilitated support group
Study: NCT03233724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (THU)
Description: Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) once a day every Wednesday, Thursday or Friday every 3 weeks.
Study: NCT04065035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Body Firming Moisturizer
Description: Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Body Cleanser
Description: Body cleanser to be used by study participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Cleanser
Description: Body cleanser to be used by study participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of moisturizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of moisturizer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moisturizer
Description: Placebo moisturizer is the vehicle control of the topical body firming moisturizer